1. What It Is (Mechanism of Action)

Bremelanotide (PT-141) is a synthetic cyclic heptapeptide and active metabolite of Melanotan II that selectively activates central melanocortin receptors (predominantly MC4R and MC1R) in the central nervous system to modulate sexual arousal without acting on the vascular nitric oxide pathway.

2. Clinical Indications Under Study

FDA-approved for acquired, generalized Hypoactive Sexual Desire Disorder (HSDD) in premenopausal women.

3. FDA Approval & Regulatory Status

Status:FDA-Approved Prescription Drug (Vyleesi)

FDA-Approved Prescription Drug (Vyleesi)

4. Human Clinical Evidence Summary

Phase 3 RECONNECT trials (n=1,247) demonstrated statistically significant increases in sexual desire scores and reductions in distress related to low sexual desire compared to placebo.

5. Known Risks, Side Effects & Boxed Warnings

Frequent transient nausea (40% of patients), facial flushing (20%), headache (11%), vomiting, and acute transient elevations in blood pressure and reductions in heart rate following subcutaneous injection. Contraindicated in uncontrolled hypertension or cardiovascular disease.

7. Why Gray-Market "Research Chemical" Versions Are Risky

Unregulated 'PT-141' powders sold online lack auto-injector dosage control, often leading to acute hypertensive spikes, severe protracted nausea, and focal hyperpigmentation.
Peptides Agora Intelligence Wire
Weekly Research Brief

Get Breaking Bremelanotide (PT-141) Clinical Trial Alerts

Receive verified FDA dockets, Phase 3 readouts, and independent HPLC lab audits directly from our medical journalism desk.

HPLC Purity Audits
Independent lab test readouts & endotoxin assays
FDA PCAC Advisory
503A / 503B compounding votes and legal dockets
Phase 2/3 Readouts
Incretin & repair peptide clinical trial data
Zero vendor sponsorship or commercial advertisingUnsubscribe anytime with one click

8. Questions to Ask a Licensed Clinician

If you are discussing this compound with your doctor or healthcare provider, consider bringing these evidence-based questions:

  • Q1: Am I a candidate for FDA-approved bremelanotide (Vyleesi) for hypoactive sexual desire disorder?
  • Q2: How should my blood pressure be evaluated prior to initiating treatment?
  • Q3: What are the guidelines regarding dosing frequency and avoiding nausea?

9. Primary Peer-Reviewed Sources & Citations

  • [1] Kingsberg SA, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials (RECONNECT). Obstet Gynecol. 2019;134(5):899-908. PubMed / Source →
  • [2] U.S. FDA Drug Approval Package: VYLEESI (bremelanotide injection). Reference ID: 4452589. PubMed / Source →